Lineage Cell Therapeutics Inc LCTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Lineage Provides Update on ReSonance® Program for Hearing Loss
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
Trading Information
- Previous Close Price
- $0.82
- Day Range
- $0.77–0.84
- 52-Week Range
- $0.77–1.99
- Bid/Ask
- $0.78 / $0.84
- Shares Outstanding
- 252.95M
- Market Cap
- $195.26M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 77
- Website
- https://www.lineagecell.com
Valuation
Metric | LCTX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.09 |
Price/Sales | 19.31 |
Price/Cash Flow | — |
Price/Earnings
LCTX
Financial Strength
Metric | LCTX |
|---|---|
Quick Ratio | 5.80 |
Current Ratio | 5.96 |
Interest Coverage | — |
Quick Ratio
LCTX
Profitability
Metric | LCTX |
|---|---|
Return on Assets (Normalized) | −12.86% |
Return on Equity (Normalized) | −26.83% |
Return on Invested Capital (Normalized) | −28.47% |
Return on Assets
LCTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|WlMpz^@ | LOCK|R<%NF | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|g$l$x@ | LOCK|@p!g | $96B | |||
| Moderna Inc MRNA | LOCK|wMXv>> | LOCK|^>v | $81B | |||
| argenx SE ADR ARGX | LOCK|N$wMq% | LOCK|!! | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|XHmd<! | LOCK|>@& | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|ccC#vRZ< | LOCK|t>!% | $30B | |||
| Incyte Corp INCY | LOCK|R$>v?c% | LOCK|t^ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|$d#!r!^ | LOCK|vK | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|@@#n!b | LOCK|kj&qf | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|%^Vs?#Q | LOCK|ZBf | $15B |